Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-25T15:00:46.082Z Has data issue: false hasContentIssue false
  • English
  • Français

Monoamine Oxidase Activity: A Genetic Marker of Schizophrenia?

Published online by Cambridge University Press:  01 August 2014

F. Owen ,
A. Pauline Ridges  and
I. B. Cookson
F. Owen
Affiliation:
Department of Psychiatry, The University of Liverpool, Great Britain
A. Pauline Ridges*
Affiliation:
Department of Psychiatry, The University of Liverpool, Great Britain
I. B. Cookson
Affiliation:
Department of Psychiatry, The University of Liverpool, Great Britain
*
Department of Psychiatry, Life Science Building, Crown Street, Liverpool L69 3BX, Great Britain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The results of pilot studies of the activities of platelet monoamine oxidase (MAO) and catechol-0-methyl transferase (COMT) in the blood of selected schizophrenics and the families of schizophrenics is presented.

No statistically significant difference was found between the blood COMT levels of 21 control subjects and 26 schizophrenics, whereas the values found for platelet MAO activity were significantly lower for the schizophrenic group than for the control group.

In one acutely disturbed first-admission schizophrenic the platelet MAO activity increased to a normal level in parallel with the clinical improvement, whereas in the relapsing schizophrenics the platelet MAO activity remained at its initial level although the clinical picture improved. No consistent findings with regard to the platelet MAO activity emerged from the study of 3 families having a history of schizophrenia.

Type
8. Free Contributions: Fourth Group
Information
Acta geneticae medicae et gemellologiae: twin research , Volume 23 , supplement S1 , January 1974 , pp. 371 - 376
Copyright
Copyright © The International Society for Twin Studies 1974

References

REFERENCES

Axelrod, J., Cohn, C.K. 1971. Methyltransferase enzymes in red blood cells. J. Pharmacol. Exp. Ther., 176: 650–654.Google Scholar
Bourdillon, R.E., Ridges, A.P. 1970. Catecholamines and schizophrenia. In Himwich, H.E. (ed.): Biochemistry, Schizophrenias and Affective Illnesses, (pp. 123–152). Baltimore: Williams and Wilkins.Google Scholar
Morrison, J., Clancy, J., Crowe, R., Winokur, G. 1972. The Iowa 500: 1. Diagnostic validity in mania depression and schizophrenia. Arch. Gen. Psychiatry, 27: 457–461.Google Scholar
Murphy, D.L., Wyatt, R.J. 1972. Reduced monoamine oxidase activity in blood platelets from schizophrenic patients. Nature (Lond.), 238: 225–226.Google Scholar
Ridges, A.P., Bourdillon, R.E., Leslie, S.A., Harper, P. 1968. «Pink spot» and schizophrenia. Psychiatr. Clin., 1: 44–62.Google Scholar
Robinson, D.S., Lovenberg, W., Keiser, H., Sjoerdsma, A. 1968. Effects of drugs on human blood platelet and plasma amine oxidase activity in vitro and in vivo. Biochem. Pharmacol., 17: 109–119.CrossRefGoogle ScholarPubMed
Robinson, D.S., Davis, J.M., Nies, A., Ravaris, C.L., Sylwester, D. 1971. Relation of sex and aging to monoamine oxidase activity of human brain, plasma and platelets. Arch. Gen. Psychiatry, 24: 536–539.Google Scholar
Shields, J. 1968. Schizophrenia: summary of the genetic evidence. J. Psychiatr. Res., 6 (Suppl. 1): 95–126.Google Scholar
Shulman, N.R., Marder, W.J., Hiller, M.C., Collier, E.N. 1964. Platelet and leukocyte isoantigens and their antibodies: serologic, physiologic and clinical studies. Prog. Hematol., 4: 222–304.Google Scholar
Wyatt, R.J., Murphy, D.L., Belmaker, R., Cohen, S., Donnelly, C.H., Pollin, W. 1973. Reduced monoamine oxidase activity in platelets: a possible genetic marker for vulnerability to schizophrenia. Science, 179: 916–918.Google Scholar